Cowen and Company’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
– Sell
-176,942
Closed -$1.61M – 677
2022
Q4
$1.61M Sell
176,942
-276,858
-61% -$2.42M 0.17% 71
2022
Q3
$1.54M Buy
453,800
+295,716
+187% +$2.61M 0.15% 62
2022
Q2
$1.19M Sell
158,084
-1,486
-0.9% -$12.9K 0.11% 86
2022
Q1
$1.5M Buy
159,570
+3,939
+3% +$32.9K 0.14% 86
2021
Q4
$1.25M Buy
+155,631
New +$1.4M 0.11% 149

Other funds holding TEVA

Cowen and Company's TEVA Position: Q1 2023 in Review

Cowen and Company sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q1 2023, closing a stake of 176,942 shares — an estimated $1.61M sold.

Cowen and Company first reported a position in TEVA in Q4 2021 and held it in 5 quarters. The position peaked at $1.61M in Q4 2022. 438 funds tracked by Wall St. Rank hold TEVA as of Q1 2023.

  • Cowen and Company reported no remaining Teva Pharmaceutical Industries Limited position as of Q1 2023 after selling out during the quarter.
  • Cowen and Company sold 176,942 Teva Pharmaceutical Industries Limited shares in Q1 2023, an estimated $1.61M.
  • Cowen and Company first reported a position in Teva Pharmaceutical Industries Limited in Q4 2021 and held it in 5 quarters.
  • Cowen and Company's Teva Pharmaceutical Industries Limited position peaked at $1.61M in Q4 2022.
  • 438 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q1 2023.

Based on Cowen and Company's 13F filing for Q1 2023, filed 9 May 2023.